Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APMNASDAQ:CRDLTSE:ITHNASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$1.04+3.5%$0.88$0.46▼$7.49$5.53M-0.16611,410 shs56,662 shsCRDLCardiol Therapeutics$1.31+5.6%$1.05$0.77▼$3.12$108.22M0.98359,035 shs292,900 shsITHInternational Tower Hill MinesC$1.39+17.8%C$0.97C$0.57▼C$1.48C$195.15M1.1736,075 shs125,939 shsVIRVir Biotechnology$5.24+3.3%$5.47$4.32▼$14.45$723.68M1.361.40 million shs1.23 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group+10.99%+12.63%+7.53%+7.18%-79.92%CRDLCardiol Therapeutics-0.40%+12.73%+8.77%+9.73%-52.67%ITHInternational Tower Hill Mines+5.36%-7.81%+24.21%+68.57%+45.68%VIRVir Biotechnology+4.32%+12.67%-17.69%-38.17%-50.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group1.8411 of 5 stars0.05.00.00.03.41.70.6CRDLCardiol Therapeutics2.4495 of 5 stars3.74.00.00.02.00.00.6ITHInternational Tower Hill MinesN/AN/AN/AN/AN/AN/AN/AN/AVIRVir Biotechnology2.8683 of 5 stars3.41.00.00.02.73.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/ACRDLCardiol Therapeutics 3.40Buy$8.67561.58% UpsideITHInternational Tower Hill Mines 0.00N/AN/AN/AVIRVir Biotechnology 2.86Moderate Buy$32.86527.64% UpsideCurrent Analyst Ratings BreakdownLatest VIR, APM, CRDL, and ITH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.005/22/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.005/12/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.004/17/2025VIRVir BiotechnologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $21.004/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K12.87N/AN/A$2.97 per share0.35CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AITHInternational Tower Hill MinesN/AN/AC$0.06 per share22.50C$0.29 per shareN/AVIRVir Biotechnology$14.30M50.60N/AN/A$11.82 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$2.83MN/A0.00∞N/AN/AN/AN/AN/ACRDLCardiol Therapeutics-$20.84M-$0.34N/AN/AN/AN/A-194.40%-129.07%7/14/2025 (Estimated)ITHInternational Tower Hill Mines-C$2.36M-C$0.02N/A∞N/AN/A-5.82%-3.65%N/AVIRVir Biotechnology-$615.06M-$4.22N/AN/AN/A-678.40%-36.71%-31.00%7/30/2025 (Estimated)Latest VIR, APM, CRDL, and ITH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025VIRVir Biotechnology-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum Group0.241.16N/ACRDLCardiol Therapeutics0.012.492.49ITHInternational Tower Hill MinesN/A10.3730.48VIRVir BiotechnologyN/A8.948.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%CRDLCardiol Therapeutics12.49%ITHInternational Tower Hill Mines71.80%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%CRDLCardiol Therapeutics5.25%ITHInternational Tower Hill Mines0.51%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.87 millionNot OptionableCRDLCardiol Therapeutics2082.61 million78.27 millionNot OptionableITHInternational Tower Hill Mines220140.40 millionN/ANot OptionableVIRVir Biotechnology580138.24 million116.24 millionOptionableVIR, APM, CRDL, and ITH HeadlinesRecent News About These CompaniesJanet Napolitano Sells 3,200 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockJune 3 at 4:59 AM | insidertrades.comNuveen Asset Management LLC Has $2.64 Million Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)June 3 at 3:37 AM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Price Down 7.6% - Here's What HappenedMay 31 at 12:48 PM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading 6.6% Higher - What's Next?May 30, 2025 | marketbeat.comVir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and OncologyMay 29, 2025 | investing.comVir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025May 28, 2025 | businesswire.comVoloridge Investment Management LLC Lowers Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)May 28, 2025 | marketbeat.comWoodline Partners LP Makes New $991,000 Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)May 28, 2025 | marketbeat.comMillennium Management LLC Has $12.59 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)May 26, 2025 | marketbeat.comVir Biotechnology's (VIR) Buy Rating Reaffirmed at Needham & Company LLCMay 24, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of VIR Q2 EarningsMay 24, 2025 | marketbeat.comGilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programsMay 22, 2025 | fiercebiotech.comVir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)May 22, 2025 | benzinga.comPoint72 Asset Management L.P. Raises Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)May 22, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by D. E. Shaw & Co. Inc.May 21, 2025 | marketbeat.comStonepine Capital Management LLC Takes Position in Vir Biotechnology, Inc. (NASDAQ:VIR)May 20, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 20, 2025 | marketbeat.comSphera Funds Management LTD. Boosts Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)May 18, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Algert Global LLCMay 16, 2025 | marketbeat.comOrbimed Advisors LLC Reduces Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)May 15, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Hudson Bay Capital Management LPMay 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVIR, APM, CRDL, and ITH Company DescriptionsAptorum Group NASDAQ:APM$1.03 +0.04 (+3.50%) Closing price 03:58 PM EasternExtended Trading$1.03 0.00 (-0.39%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Cardiol Therapeutics NASDAQ:CRDL$1.31 +0.07 (+5.65%) Closing price 04:00 PM EasternExtended Trading$1.31 +0.00 (+0.31%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.International Tower Hill Mines TSE:ITHC$1.39 +0.21 (+17.80%) As of 03:59 PM EasternInternational Tower Hill Mines Ltd. engages in the acquisition, exploration, and development of mineral properties. It holds rights to acquire interests in the Livengood gold project covering an area of approximately 19,546 hectares located to the northwest of Fairbanks, Alaska. The company was formerly known as Tower Hill Mines Ltd. and changed its name to International Tower Hill Mines Ltd. in March 1991. International Tower Hill Mines Ltd. was incorporated in 1978 and is headquartered in Vancouver, Canada.Vir Biotechnology NASDAQ:VIR$5.24 +0.17 (+3.25%) Closing price 03:59 PM EasternExtended Trading$5.20 -0.04 (-0.76%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
